Stockholm, September 6, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), announced today that it will present two posters on its lead program, C21, under development for the treatment of idiopathic pulmonary fibrosis (IPF), at the European Respiratory Society […]